Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) patients, where both microenvironment and cell-regulatory mechanisms contribute to disease pathogenesis. The objective of this multicenter, phase 2 expansion trial was to determine the efficacy and safety of combinati...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sekeres, Mikkael A., Tiu, Ramon V., Komrokji, Rami, Lancet, Jeffrey, Advani, Anjali S., Afable, Manuel, Englehaupt, Ricki, Juersivich, Joyce, Cuthbertson, David, Paleveda, Jennifer, Tabarroki, Ali, Visconte, Valeria, Makishima, Hideki, Jerez, Andres, Paquette, Ronald, List, Alan F., Maciejewski, Jaroslaw P.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2012
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3525020/
https://ncbi.nlm.nih.gov/pubmed/22915641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-06-434639
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires